** Shares of Simcere Pharmaceutical Group Ltd 2096.HK jump 5.5% to HK$8.07, their biggest intraday pct gain since February 18
** Stock on course for a third consecutive session of gains, if current trend holds
** Simcere Pharmaceutical says its anti-tumor drug candidate - SIM0686 - has obtained a Clinical Trial Approval, issued by China's National Medical Products Administration (NMPA)
** SIM0686 is an FGFR2b Antibody-Drug Conjugate for treatment of gastric cancer and lung cancer
** Hong Kong's healthcare index .HSCIH rises 2.1%, Hang Seng Index .HSI rises 1.8%
** Stock up 7.8% YTD
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。